Literature DB >> 32506714

Identifying Progression in Multiple Sclerosis: New Perspectives.

Massimo Filippi1,2,3,4, Paolo Preziosa1,2, Dawn Langdon5, Hans Lassmann6, Friedemann Paul7, Àlex Rovira8, Menno M Schoonheim9, Alessandra Solari10, Bruno Stankoff11, Maria A Rocca1,2.   

Abstract

The identification of progression in multiple sclerosis is typically retrospective. Given the profound burden of progressive multiple sclerosis, and the recent development of effective treatments for these patients, there is a need to establish measures capable of identifying progressive multiple sclerosis early in the disease course. Starting from recent pathological findings, this review assesses the state of the art of potential measures able to predict progressive multiple sclerosis. Future promising biomarkers that might shed light on mechanisms of progression are also discussed. Finally, expansion of the concept of progressive multiple sclerosis, by including an assessment of cognition, patient-reported outcomes, and comorbidities, is considered. ANN NEUROL 2020;88:438-452.
© 2020 American Neurological Association.

Entities:  

Mesh:

Year:  2020        PMID: 32506714     DOI: 10.1002/ana.25808

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  13 in total

Review 1.  N6-methyladenosine and Neurological Diseases.

Authors:  Nan Zhang; Chunhong Ding; Yuxin Zuo; Yu Peng; Lielian Zuo
Journal:  Mol Neurobiol       Date:  2022-01-15       Impact factor: 5.590

2.  Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers.

Authors:  Monica Margoni; Paolo Preziosa; Paola Tortorella; Massimo Filippi; Maria A Rocca
Journal:  Neurotherapeutics       Date:  2022-06-06       Impact factor: 6.088

Review 3.  Osteopontin in autoimmune disorders: current knowledge and future perspective.

Authors:  Canhua Xu; Yaohong Wu; Ning Liu
Journal:  Inflammopharmacology       Date:  2022-03-02       Impact factor: 5.093

Review 4.  Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives.

Authors:  Elisabeth G Celius; Heidi Thompson; Maija Pontaga; Dawn Langdon; Alice Laroni; Stanca Potra; Trishna Bharadia; David Yeandle; Jane Shanahan; Pieter van Galen; Nektaria Alexandri; Jürg Kesselring
Journal:  Patient Prefer Adherence       Date:  2021-01-08       Impact factor: 2.711

Review 5.  Should We Use Clinical Tools to Identify Disease Progression?

Authors:  Hernan Inojosa; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  Front Neurol       Date:  2021-01-21       Impact factor: 4.003

6.  Discovery of Novel Biomarkers for Diagnosing and Predicting the Progression of Multiple Sclerosis Using TMT-Based Quantitative Proteomics.

Authors:  Yijun Shi; Yaowei Ding; Guoge Li; Lijuan Wang; Rasha Alsamani Osman; Jialu Sun; Lingye Qian; Guanghui Zheng; Guojun Zhang
Journal:  Front Immunol       Date:  2021-08-20       Impact factor: 7.561

Review 7.  [Neuropsychological and MRI diagnostics in secondary progressive multiple sclerosis].

Authors:  I-K Penner; A Gass; H Schreiber; M P Wattjes
Journal:  Nervenarzt       Date:  2021-04-23       Impact factor: 1.297

8.  Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes?

Authors:  Daniele Belvisi; Matteo Tartaglia; Giovanna Borriello; Viola Baione; Sebastiano Giuseppe Crisafulli; Valeria Zuccoli; Giorgio Leodori; Antonio Ianniello; Gabriele Pasqua; Patrizia Pantano; Alfredo Berardelli; Carlo Pozzilli; Antonella Conte
Journal:  Biomedicines       Date:  2022-01-21

Review 9.  Telemedicine as a strategic intervention for cognitive rehabilitation in MS patients during COVID-19.

Authors:  Fereshteh Ghadiri; Abdorreza Naser Moghadasi; Mohammad Ali Sahraian
Journal:  Acta Neurol Belg       Date:  2022-01-30       Impact factor: 2.471

Review 10.  [Disease-modifying treatment of secondary progressive multiple sclerosis].

Authors:  Olaf Hoffmann; Ralf Gold
Journal:  Nervenarzt       Date:  2021-03-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.